DR info

臨床試験数 : 15 / 薬物数 : 26 - (DrugBank : 16) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 105

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Anti-thymocyte globulin
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Autologous Peripheral Blood Stem Cell Transplantation
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Azathioprine
   Hospices Civils de Lyon
      1996   Phase 4   NCT00400075   Switzerland;
   University of Pennsylvania
      2017   Phase 2   NCT02939573   Canada;Japan;United States;
CellCept (Mycophenolate Mofetil)
   University College London
      2016   Phase 3   EUCTR2013-004668-71-IT   Belgium;Croatia;Czech Republic;Germany;Greece;Italy;Netherlands;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2013-004668-71-ES   Belgium;Croatia;Czech Republic;Germany;Greece;Italy;Netherlands;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-004668-71-GB   Belgium;Croatia;Czech Republic;Germany;Greece;Italy;Netherlands;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      -   Phase 3   EUCTR2013-004668-71-PT   Belgium;Croatia;Czech Republic;Germany;Greece;Italy;Netherlands;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      -   Phase 3   EUCTR2013-004668-71-BE   Belgium;Croatia;Czech Republic;Germany;Greece;Italy;Netherlands;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
Colchicine
   University of Pennsylvania
      2017   Phase 2   NCT02939573   Canada;Japan;United States;
Corticosteroid and azathioprine
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 3   NCT00647166   France;
Cyclophosphamide
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
   Hospices Civils de Lyon
      1996   Phase 4   NCT00400075   Switzerland;
   University College London
      2016   Phase 3   EUCTR2013-004668-71-IT   Belgium;Croatia;Czech Republic;Germany;Greece;Italy;Netherlands;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-004668-71-GB   Belgium;Croatia;Czech Republic;Germany;Greece;Italy;Netherlands;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
   University of Parma
      2008   Phase 2   NCT00751517   Italy;
Cyclophosphamide, Azathioprine,prednisone,methylprednisolone
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 4   NCT00307671   France;
Cyclosporine
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Dapsone
   University of Pennsylvania
      2017   Phase 2   NCT02939573   Canada;Japan;United States;
Filgrastim
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Infliximab
   Cambridge University Hospitals NHS Foundation Trust
      2020   Phase 2   EUCTR2019-003964-30-GB   United Kingdom;
Lamivudine
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1995   Phase 2   NCT00001457   United States;
Methotrexate
   University of Parma
      2008   Phase 2   NCT00751517   Italy;
Methylprednisolone
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Mycophenolate mofetil,methotrexate
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 4   NCT00307671   France;
Naltrexone Hydrochloride
   University of Pennsylvania
      2019   Phase 2   NCT03482479   United States;
Prednisone
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Prednisone, methylprednisolone,cyclophosphamides
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 4   NCT00307671   France;
Rituximab
   Cambridge University Hospitals NHS Foundation Trust
      2020   Phase 2   EUCTR2019-003964-30-GB   United Kingdom;
Tocilizumab
   Cambridge University Hospitals NHS Foundation Trust
      2020   Phase 2   EUCTR2019-003964-30-GB   United Kingdom;